Ke Sharon, Kil Hyein, Roggy Conner, Shields Ty, Quinn Zachary, Quinn Alyssa P, Small James M, Towne Francina D, Brooks Amanda E, Brooks Benjamin D
Department of Biomedical Sciences, College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80134, USA.
Department of Surgery, Virtua Health, Camden, NJ 08103, USA.
Antibiotics (Basel). 2024 Nov 5;13(11):1046. doi: 10.3390/antibiotics13111046.
Despite the significant advances in antibiotic treatments and therapeutics, () remains a formidable pathogen, primarily due to its rapid acquisition of antibiotic resistance. Known for its array of virulence factors, including surface proteins that promote adhesion to host tissues, enzymes that break down host barriers, and toxins that contribute to immune evasion and tissue destruction, poses a serious health threat. Both the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) classify as an ESKAPE pathogen, recognizing it as a critical threat to global health. The increasing prevalence of drug-resistant underscores the need for new therapeutic strategies. This review discusses a promising approach that combines monoclonal antibodies targeting multiple epitopes, offering synergistic efficacy in treating infections. Such strategies aim to reduce the capacity of the pathogen to develop resistance, presenting a potent adjunct or alternative to conventional antibiotic treatments.
尽管抗生素治疗和疗法取得了重大进展,但()仍然是一种 formidable 病原体,主要是因为它能迅速获得抗生素耐药性。以其一系列毒力因子而闻名,包括促进与宿主组织粘附的表面蛋白、分解宿主屏障的酶以及有助于免疫逃避和组织破坏的毒素,()构成了严重的健康威胁。疾病控制与预防中心(CDC)和世界卫生组织(WHO)都将()归类为 ESKAPE 病原体,认为它是对全球健康的重大威胁。耐药()的日益流行凸显了新治疗策略的必要性。本综述讨论了一种有前景的方法,该方法结合了针对多个()表位的单克隆抗体,在治疗感染方面具有协同疗效。此类策略旨在降低病原体产生耐药性的能力,是传统抗生素治疗的有力辅助手段或替代方法。
原文括号处内容缺失,无法准确完整翻译。